Adakveo®

Adakveo® (crizanlizumab-tmca) is a prescription medicine used in people 16 years of age and older who have sickle cell disease to help reduce frequency of painful episodes Adakveo helps prevent pain crises (called vaso-occlusive crises, or VOCs) in patients with sickle cell disease (SCD). Vaso-occlusive crises occur when microcirculation is obstructed by “sickled” red blood cells. Adakveo works by binding to P-selectin, a protein that plays a central role in cellular interactions that can lead to vaso-occlusion. In its initial study, Adakveo was shown to reduce VOCs by about 45%.

For more information, visit the patient website for this drug. *Some browsers may reroute this link to the Prescribing Information.

Speak with your healthcare provider to learn if this drug is right for you.

Adakveo® Referral Form